PHASED ARRAY TRANSDUCER - - PVF -375DT
K972771 · Toshiba America Medical Systems, In.C · ITX · Feb 11, 1998 · Radiology
Device Facts
| Record ID | K972771 |
| Device Name | PHASED ARRAY TRANSDUCER - - PVF -375DT |
| Applicant | Toshiba America Medical Systems, In.C |
| Product Code | ITX · Radiology |
| Decision Date | Feb 11, 1998 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 892.1570 |
| Device Class | Class 2 |
Intended Use
Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Intended Use- Additional Comments: This transducer is indicated for adjunctive non-quantitative visualization of the target study area.
Device Story
PVF-375DT is a convex phased array ultrasound transducer designed for use with Toshiba SSA-340A, SSA-270A, and SSH-140A imaging systems. It captures acoustic signals to generate diagnostic ultrasound images and perform fluid flow analysis. The device introduces volume imaging capabilities to assist with patient education during examinations. Operated by trained clinicians in a clinical setting, the transducer transmits and receives ultrasound waves, which the host system processes into visual outputs. These outputs provide non-quantitative visualization of fetal and abdominal anatomy, aiding clinicians in diagnostic assessments. The device benefits patients by facilitating clearer communication and understanding of their diagnostic findings during ultrasound procedures.
Clinical Evidence
No clinical data. Substantial equivalence is based on technological similarities to the predicate device and adherence to previously cleared verification and validation procedures. Bench testing of acoustic output is required post-clearance.
Technological Characteristics
Convex phased array transducer; intended for use with SSA-340A, SSA-270A, and SSH-140A ultrasound systems. Employs standard ultrasound piezoelectric technology. No changes to patient contact materials or acoustic output intensities compared to predicate. Prescription device.
Indications for Use
Indicated for diagnostic ultrasound imaging or fluid flow analysis in fetal and abdominal applications, including M-mode, B-mode, and pulsed wave Doppler (PWD). Intended for adjunctive non-quantitative visualization of the target study area.
Regulatory Classification
Identification
A diagnostic ultrasonic transducer is a device made of a piezoelectric material that converts electrical signals into acoustic signals and acoustic signals into electrical signals and intended for use in diagnostic ultrasonic medical devices. Accessories of this generic type of device may include transmission media for acoustically coupling the transducer to the body surface, such as acoustic gel, paste, or a flexible fluid container.
Predicate Devices
- PVF-375MT convex transducer
Related Devices
- K080935 — SONIX MDP ULTRASOUND SCANNER · Ultrasonix Medical Corporation · Aug 6, 2008
- K081110 — SIUI CTS-900 DIGITAL ULTRASOUND IMAGING SYSTEM · Shantou Institute of Ultrasonic Instuments · May 16, 2008
- K974544 — ASU-1000 DIAGNOSTIC ULTRASOUND TRANSDUCER · Aloka Co., Ltd. · Mar 18, 1998
- K081661 — HD15 DIAGNOSTIC ULTRASOUND SYSTEM · Philips Ultrasound, Inc. · Jun 24, 2008
- K041455 — SSI-600/SSI-800 DIAGNOSTIC ULTRASOUND IMAGING SYSTEM · Sonoscape Company Limited · Jun 10, 2004
Submission Summary (Full Text)
{0}------------------------------------------------
## FEB 11 1998 510(k) Summary
Toshiba America Medical Systems, Inc. Submitter's Name: P.O. Box 2068, 2441 Michelle Drive, Tustin CA 92781-2068 Submitter's Address: Steven M. Kay, Regulatory Affairs Specialist, (714) 730-5000 Submitter's Contact: Establishment Registration Number: 2020563
Phased Array Transducer - - PVF-375DT Device Proprietary Name: Diagnostic Ultrasound Transducer Common Name: [Fed. Reg. No .: 892.1570, Pro. Code: 90-ITX]
Regulatory Class: II 514 Performance Standards: None Special Controls: None Prescription Status: Prescription Device
Modification of the PVF-375MT Reason for Submission:
## Substantial Equivalence Summary:
The PVF-375DT volume imaging transducer is a modification of the PVF-375MT convex transducer that was cleared for the SSA-340A, SSA-270A and SSH-140A diagnostic ultrasound imaging systems. It will add volume imaging to conventional diagnostic ultrasound images. Volume imaging is due to the physical characteristics of the device and is intended to assist with patient education during an examination.
The PVF-375DT follows previously cleared software verification and validation procedures and employs the same general technology as that most lately cleared for the PVF-375MT. It does not affect cleared patient contact materials or acoustic output intensities. Based on a review of TAMS Complaint and MDR files for similar transducers, any potential failure of this transducer is not expected to result in an injury to the patient.
TAMS believes that the PVF-375DT is substantially equivalent to the PVF-375MT because it does not change the cleared safety and effectiveness attributes or the indications for use of the PVF-375MT.
{1}------------------------------------------------
Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized depiction of a human figure with outstretched arms, symbolizing protection and care. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES · USA" is arranged in a circular pattern around the figure, emphasizing the department's name and national scope.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
FEB 1 1 1898
Paul Biggins Regulatory Affairs Specialist Toshiba America Medical Systems, Inc. 2441 Michelle Drive P.O. Box 2068 Tustin, CA 92781-2068
Re: K972771 Phased Array Tranducer - PVF-375DT Dated: November 7, 1997 Received: November 13, 1997 Regulatory class: II 21 CFR 892.1570/Procode: 90 ITX
Dear Mr. Biggins:
We have reviewed your section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug and Cosmetic Act. You may, therefore, market the device, subject to the general controls provisions Act (Act). The general controls provisions of the Act include requirements for registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration.
This determination of substantial equivalence applies to the following transducers intended for use with the SSA-340A, SSA-270 and SSA-140A Ultrasound Systems, as described in your premarket notification:
## Transducer Model Number
## PVF-375DT
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic QS inspections, the FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification does not affect any obligation you may have under sections 531 and 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.
{2}------------------------------------------------
Page 2 - Paul Biggins
The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:
> Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850
This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (2) CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
If you have any questions regarding the content of this letter, please contact Robert Phillips, Ph.D. at (301) 594-1212.
Sincerely vours.
David A. Segerman
Lillian Yin, Ph.D.
Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosures
{3}------------------------------------------------
| | Ultrasound Device Indications Statement Page | 1 of 1 |
|---------------------------|----------------------------------------------|--------|
| 510(k) Number (if known): | K972771 | |
| Device Name: | PVF-375DT convex phased array transducer | |
Fill out one form for each ultrasound system and each transducer.
| Clinical Application | A | B | M | PWD | CWD | Color<br>Doppler | Power<br>(Amplitude)<br>Doppler | Color<br>Velocity<br>Imaging | Combined<br>(Specify) | Other<br>(Specify) |
|---------------------------------|---|---|---|-----|-----|------------------|---------------------------------|------------------------------|-----------------------|--------------------|
| Ophthalmic | | | ✓ | | | | | | | |
| Fetal | | ✓ | ✓ | ✓ | | | | | | |
| Abdominal | | ✓ | ✓ | ✓ | | | | | | |
| Intra-operative<br>(Specify) | | | | | | | | | | |
| Intra-operative<br>Neurological | | | | | | | | | | |
| Pediatric | | | | | | | | | | |
| Small Organ<br>(Specify) | | | | | | | | | | |
| Neonatal Cephalic | | | | | | | | | | |
| Adult Cephalic | | | | | | | | | | |
| Cardiac | | | | | | | | | | |
| Trans-Esophageal | | | | | | | | | | |
| Trans-Rectal | | | | | | | | | | |
| Trans-Vaginal | | | | | | | | | | |
| Trans-Urethral | | | | | | | | | | |
| Intra-Luminal | | | | | | | | | | |
| Peripheral<br>Vascular | | | | | | | | | | |
| Laparascopic | | | | | | | | | | |
| Musculo-Skeletal | | | | | | | | | | |
| Other (Specify) | | | | | | | | | | |
Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows: Intended Use-
Additional Comments: This transducer is indicated for adjunctive non-quantitative visualization of the target study area.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
David A. Seymour
chictive. Abdominal. El . 10(k) Number